Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
140 hedge funds and large institutions have $1.61B invested in Amicus Therapeutics in 2015 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 55 increasing their positions, 34 reducing their positions, and 26 closing their positions.
80% more capital invested
Capital invested by funds: $892M → $1.61B (+$715M)
62% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 34
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
21% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $12M
12% more funds holding
Funds holding: 125 → 140 (+15)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$151M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$62.6M |
| 3 |
Jennison Associates
New York
|
+$40.5M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$35M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$26.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.6M |
| 2 |
Morgan Stanley
New York
|
-$11.9M |
| 3 |
D.E. Shaw & Co
New York
|
-$11.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$10.5M |
| 5 |
ICAP
Independence Capital Asset Partners
Denver,
Colorado
|
-$7.24M |
FOLD Hedge Fund Activity: Q2 2015 in Review
140 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2015, worth a combined $1.61B — up 80% from $892M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new FOLD positions and 26 closed out — a net gain of 15 holders — while 55 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $151M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $15.6M sold.
- 140 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2015, up from 125 in Q1 2015.
- Funds reported $1.61B of Amicus Therapeutics stock for Q2 2015, up 80% quarter-over-quarter.
- 41 funds opened new Amicus Therapeutics positions in Q2 2015 and 26 closed out, a net change of +15 holders.
- The largest Amicus Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $151M added.
- The largest Amicus Therapeutics seller in Q2 2015 was Balyasny Asset Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q2 2015.